alosetron has been researched along with Colitis, Ischemic in 15 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
Colitis, Ischemic: Inflammation of the COLON due to colonic ISCHEMIA resulting from alterations in systemic circulation or local vasculature.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies." | 8.83 | Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. ( Chang, L; Chey, WD; Harris, L; Olden, K; Schoenfeld, P; Surawicz, C, 2006) |
| "Alosetron is a potent, selective 5-HT(3) receptor antagonist prescribed for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D) under a risk management plan (RMP)." | 7.76 | Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. ( Ameen, V; Chang, L; Tong, K, 2010) |
| " Initial use was widespread, but infrequent serious adverse events of ischemic colitis and severe constipation-related complications prompted alosetron's voluntary withdrawal from the US market in November 2000." | 5.36 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. ( Lewis, JH, 2010) |
| "Because the mechanism(s) of drug-induced ischemic colitis and possibly other forms of intestinal ischemia associated with alosetron have not been elucidated, there is need to further assess risk with regard to patient susceptibility and other factors." | 5.33 | Alosetron: ischemic colitis and serious complications of constipation. ( Avigan, M; Brinker, A; Gallo-Torres, H, 2006) |
| "Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies." | 4.83 | Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. ( Chang, L; Chey, WD; Harris, L; Olden, K; Schoenfeld, P; Surawicz, C, 2006) |
| "More than one decade ago, rising cases of ischemic colitis (IC) prompted the Federal Drug Administration to revoke alosetron's approval as treatment of irritable bowel syndrome (IBS)." | 3.83 | Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System. ( Bielefeldt, K, 2016) |
| "Alosetron is a potent, selective 5-HT(3) receptor antagonist prescribed for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D) under a risk management plan (RMP)." | 3.76 | Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. ( Ameen, V; Chang, L; Tong, K, 2010) |
| " Initial use was widespread, but infrequent serious adverse events of ischemic colitis and severe constipation-related complications prompted alosetron's voluntary withdrawal from the US market in November 2000." | 1.36 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. ( Lewis, JH, 2010) |
| "Because the mechanism(s) of drug-induced ischemic colitis and possibly other forms of intestinal ischemia associated with alosetron have not been elucidated, there is need to further assess risk with regard to patient susceptibility and other factors." | 1.33 | Alosetron: ischemic colitis and serious complications of constipation. ( Avigan, M; Brinker, A; Gallo-Torres, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (73.33) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bielefeldt, K | 1 |
| Lewis, JH | 2 |
| Chang, L | 2 |
| Tong, K | 1 |
| Ameen, V | 1 |
| Avigan, M | 2 |
| Justice, R | 1 |
| Mackey, AC | 1 |
| Nair, N | 1 |
| Traynor, K | 1 |
| Smith, DA | 1 |
| Schmid, EF | 1 |
| Chey, WD | 1 |
| Harris, L | 1 |
| Olden, K | 1 |
| Surawicz, C | 1 |
| Schoenfeld, P | 1 |
| Gallo-Torres, H | 1 |
| Brinker, A | 1 |
| Miller, JL | 1 |
| Horton, R | 1 |
| Beck, IT | 1 |
| Camilleri, M | 1 |
| Lisi, DM | 1 |
3 reviews available for alosetron and Colitis, Ischemic
| Article | Year |
|---|---|
The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Topics: Animals; Carbolines; Colitis, Ischemic; Female; Humans; Indoles; Irritable Bowel Syndrome; Male; Ser | 2011 |
Drug withdrawals and the lessons within.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbolines; Colitis, Ischemic; Drug Design; Drug-R | 2006 |
Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.
Topics: Carbolines; Clinical Trials as Topic; Colitis, Ischemic; Constipation; Diarrhea; Female; Gastrointes | 2006 |
12 other studies available for alosetron and Colitis, Ischemic
| Article | Year |
|---|---|
Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2016 |
Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Topics: Carbolines; Colitis, Ischemic; Constipation; Diarrhea; Dose-Response Relationship, Drug; Female; Hum | 2010 |
Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
Topics: Adverse Drug Reaction Reporting Systems; Carbolines; Colitis, Ischemic; Constipation; Female; Humans | 2010 |
Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
Topics: Adverse Drug Reaction Reporting Systems; Carbolines; Clinical Trials as Topic; Colitis, Ischemic; Co | 2003 |
Alosetron use drops dramatically with risk management.
Topics: Adverse Drug Reaction Reporting Systems; Carbolines; Colitis, Ischemic; Female; Gastrointestinal Age | 2004 |
Alosetron: ischemic colitis and serious complications of constipation.
Topics: Carbolines; Colitis, Ischemic; Constipation; Gastrointestinal Agents; Humans; Irritable Bowel Syndro | 2006 |
Irritable bowel syndrome. New treatment drug on the market.
Topics: Carbolines; Colitis, Ischemic; Colonic Diseases, Functional; Constipation; Humans; Serotonin Antagon | 2000 |
FDA draws patients into alosetron risk management.
Topics: Carbolines; Colitis, Ischemic; Colonic Diseases, Functional; Constipation; Contraindications; Drug L | 2000 |
Lotronex and the FDA: a fatal erosion of integrity.
Topics: Carbolines; Colitis, Ischemic; Colonic Diseases, Functional; Drug and Narcotic Control; Drug Approva | 2001 |
Possible mechanisms for ischemic colitis during alosetron therapy.
Topics: Animals; Carbolines; Colitis, Ischemic; Constipation; Gastrointestinal Agents; Humans; Serotonin Ant | 2001 |
Safety concerns about alosetron.
Topics: Carbolines; Colitis, Ischemic; Constipation; Gastrointestinal Agents; Humans; Product Surveillance, | 2002 |
Lotronex withdrawal.
Topics: Carbolines; Colitis, Ischemic; Constipation; Gastrointestinal Agents; Humans; Product Surveillance, | 2002 |